ICU Medical (NASDAQ:ICUI) Updates FY 2026 Earnings Guidance

Key Points

• ICU Medical updated FY2026 EPS guidance to 7.750–8.450, essentially in line with the consensus estimate of 7.740, while the company did not provide revenue guidance.
• The company beat the quarter, reporting EPS of $1.97 vs. $1.78 expected and revenue of $525.77M vs. $520.65M estimated.
• Analysts have trimmed price targets to the mid‑$160s (average target $169) but the consensus rating remains a Moderate Buy

ICU Medical (NASDAQ:ICUI - Get Free Report) updated its FY 2026 earnings guidance on Thursday. The company provided earnings per share guidance of 7.750-8.450 for the period, compared to the consensus earnings per share estimate of 7.740. The company issued revenue guidance of -.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. Piper Sandler reduced their price objective on shares of ICU Medical from $178.00 to $163.00 and set an "overweight" rating on the stock in a research note on Friday, April 17th. KeyCorp reduced their price objective on shares of ICU Medical from $180.00 to $164.00 and set an "overweight" rating on the stock in a research note on Monday, April 27th. Wall Street Zen downgraded shares of ICU Medical from a "buy" rating to a "hold" rating in a research note on Saturday, April 18th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of ICU Medical in a research note on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $169.00.

ICU Medical Price Performance

ICUI stock traded up $3.48 during trading on Thursday, reaching $123.07. 351,997 shares of the company were exchanged, compared to its average volume of 275,739. The company has a 50-day moving average of $129.52 and a two-hundred day moving average of $138.31. The company has a market capitalization of $3.08 billion, a price-to-earnings ratio of 6,156.58, a P/E/G ratio of 1.69 and a beta of 0.74. ICU Medical has a twelve month low of $107.00 and a twelve month high of $160.29. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.39 and a quick ratio of 1.15.

ICU Medical (NASDAQ:ICUI - Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $1.97 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.78 by $0.19. The business had revenue of $525.77 million during the quarter, compared to analyst estimates of $520.65 million. ICU Medical had a net margin of 0.03% and a return on equity of 7.33%. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. As a group, equities analysts predict that ICU Medical will post 6.31 earnings per share for the current fiscal year.

Institutional Trading of ICU Medical

Several hedge funds have recently modified their holdings of ICUI. Millennium Management LLC increased its position in shares of ICU Medical by 173.4% during the third quarter. Millennium Management LLC now owns 1,089,017 shares of the medical instruments supplier's stock valued at $130,638,000 after buying an additional 690,694 shares during the period. UBS Group AG boosted its stake in ICU Medical by 239.8% in the third quarter. UBS Group AG now owns 386,555 shares of the medical instruments supplier's stock worth $46,371,000 after buying an additional 272,782 shares in the last quarter. Ameriprise Financial Inc. boosted its stake in ICU Medical by 34.0% in the third quarter. Ameriprise Financial Inc. now owns 803,542 shares of the medical instruments supplier's stock worth $96,393,000 after buying an additional 203,746 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in ICU Medical by 16.9% in the third quarter. Dimensional Fund Advisors LP now owns 872,993 shares of the medical instruments supplier's stock worth $104,718,000 after buying an additional 126,072 shares in the last quarter. Finally, Janus Henderson Group PLC boosted its stake in shares of ICU Medical by 4.2% during the fourth quarter. Janus Henderson Group PLC now owns 2,576,756 shares of the medical instruments supplier's stock valued at $367,625,000 after purchasing an additional 103,220 shares during the period. Institutional investors own 96.10% of the company's stock.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.